TOKYO – Takeda Pharmaceutical Co. Ltd., of Japan, plans to restructure its research and development operations to focus primarily on the areas of oncology, gastroenterology and central nervous system, as well as vaccines.

TOKYO – Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has issued a risk warning for filgrastim and a number of its biosimilars after reports that it can lead to anaphylaxis.

TOKYO – Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has issued a risk warning for filgrastim and a number of its derivatives after reports that it can lead to anaphylaxis.

TOKYO – A flurry of activity over the past month suggests that the adoption of biosimilars in Japan is about to accelerate. Partnerships with Indian and U.S. companies are bringing new biosimilars to the market, while an association for the drugs was launched to help promote awareness of their benefits.

TOKYO – A flurry of activity over the past month suggests that the adoption of biosimilars in Japan is about to accelerate. Partnerships with Indian and U.S. companies are bringing new biosimilars to the market, while an association for the drugs was launched to help promote awareness of their benefits.

TOKYO – Japan's major pharmaceutical companies have, by-and-large, managed to overcome a series of reverses including drug price reductions and a slowing economy.

TOKYO – Japan’s major pharmaceutical companies have, by-and-large, managed to overcome a series of reverses including drug price reductions and a slowing economy.

TOKYO – Japan will lower the price of Ono Pharmaceutical Inc.’s Opdivo (nivolumab) and reform the guidelines on its usage as the country looks to a future in which the price of drugs add billions in government spending.

TOKYO – Japan will lower the price of Ono Pharmaceutical Inc.'s Opdivo (nivolumab) and reform the guidelines on its usage as the country looks to a future in which the price of drugs add billions in government spending.